Trends in Cardiovascular Medicine
Volume 17, Issue 2 , Pages 63-68 , February 2007

Effect of Adenosine Triphosphate-Sensitive Potassium Channel Inhibitors on Coronary Metabolic Vasodilation

  • H.M. Omar Farouque

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Dr. H. M. Omar Farouque, 145 Studley Road, PO Box 5555, Heidelberg, Victoria, 3084, Australia. Tel.: (+61) 3-94963034; fax: (+61) 3-9459-0971.
    • ,
  • Ian T. Meredith

References 

  1. Anonymous . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [published erratum appears in Lancet 1999 Aug 14;354:602]. Lancet. 1998;352:837–853
  2. Anonymous . Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002;359:1269–1275
  3. Aronow WS, Ahn C. Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone. Am J Cardiol. 2001;88:556–557
  4. Ashcroft SJH, Aschcroft FM. Properties and function of ATP-sensitive K-channels. Cell Signal. 1990;2:197–214
  5. Aversano T, Ouyang P, Silverman H, et al. Effect of blockade of the ATP-sensitive potassium channel on metabolic coronary vasodilation in the dog. Pharmacology. 1993;47:360–368
  6. Baukrowitz T, Schulte U, Oliver D, et al. PIP2 and PIP as determinants for ATP inhibition of KATP channels. Science. 1998;282:1141–1144
  7. Beech DJ, Zhang H, Nakao K, et al. K channel activation by nucleotide diphosphates and its inhibition by glibenclamide in vascular smooth muscle cells. Br J Pharmacol. 1993;110:573–582
  8. Brady PA, Al-Suwaidi J, Kopecky SL, Terzic A. Sulfonylureas and mortality in diabetic patients after myocardial infarction. Circulation. 1998;97:709–710
  9. Brayden JE. Potassium channels in vascular smooth muscle. Clin Exp Pharmacol Physiol. 1996;23:1069–1076
  10. Clement JP, Kunjilwar K, Gonzalez G, et al. Association and stoichiometry of K(ATP) channel subunits. Neuron. 1997;18:827–838
  11. Coppack SW, Lant AF, McIntosh CS, Rodgers AV. Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus. Br J Clin Pharmacol. 1990;29:673–684
  12. Daut J, Maier-Rudolph W, Von Beckerath N, et al. Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels. Science. 1990;247:1341–1344
  13. Davis TM, Parsons RW, Broadhurst RJ, et al. Arrhythmias and mortality after myocardial infarction in diabetic patients. Relationship to diabetes treatment. Diabetes Care. 1998;21:637–640
  14. Dean PM. Electrical activity in pancreatic islet cells. Nature. 1968;219:389–390
  15. Duncker DJ, Oei HH, Hu F, et al. Role of K(ATP)(+) channels in regulation of systemic, pulmonary, and coronary vasomotor tone in exercising swine. Am J Physiol Heart Circ Physiol. 2001;280:H22–H33
  16. Duncker DJ, van Zon NS, Altman JD, et al. Role of K+ ATP channels in coronary vasodilation during exercise. Circulation. 1993;88:1245–1253
  17. Duncker DJ, van Zon NS, Ishibashi Y, Bache RJ. Role of K+ ATP channels and adenosine in the regulation of coronary blood flow during exercise with normal and restricted coronary blood flow. J Clin Invest. 1996;97:996–1009
  18. Duncker DJ, van Zon NS, Pavek TJ, et al. Endogenous adenosine mediates coronary vasodilation during exercise after K(ATP)+ channel blockade. J Clin Invest. 1995;95:285–295
  19. Farouque HM, Worthley SG, Meredith IT, et al. Effect of ATP-sensitive potassium channel inhibition on coronary metabolic vasodilation in humans. Arterioscler Thromb Vasc Biol. 2004;24:905–910
  20. Farouque HM, Worthley SG, Meredith IT, et al. Effect of ATP-sensitive potassium channel inhibition on resting coronary vascular responses in humans. Circ Res. 2002;90:231–236
  21. Feigl EO. Coronary physiology. Physiol Rev. 1983;63:1–205
  22. Findlay I. Effects of pH upon the inhibition by sulphonylurea drugs of ATP-sensitive K+ channels in cardiac muscle. J Pharmacol Exp Ther. 1992;262:71–79
  23. Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1999;33:119–124
  24. Gollasch M, Bychkov R, Ried C, et al. Pinacidil relaxes porcine and human coronary arteries by activating ATP-dependent potassium channels in smooth muscle cells. J Pharmacol Exp Ther. 1995;275:681–692
  25. Gollasch M, Ried C, Bychkov R, et al. K+ currents in human coronary artery vascular smooth muscle cells. Circ Res. 1996;78:676–688
  26. Gribble FM, Tucker SJ, Ashcroft FM. The interaction of nucleotides with the tolbutamide block of cloned ATP-sensitive K+ channel currents expressed in Xenopus oocytes: a reinterpretation. J Physiol. 1997;504(Pt 1):35–45
  27. Gribble FM, Tucker SJ, Seino S, Ashcroft FM. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels. Diabetes. 1998;47:1412–1418
  28. Henquin JC. Tolbutamide stimulation and inhibition of insulin release: studies of the underlying ionic mechanisms in isolated rat islets. Diabetologia. 1980;18:151–160
  29. Imamura Y, Tomoike H, Narishige T, et al. Glibenclamide decreases basal coronary blood flow in anesthetized dogs. Am J Physiol. 1992;263:H399–H404
  30. Ishibashi Y, Duncker DJ, Zhang J, Bache RJ. ATP-sensitive K+ channels, adenosine, and nitric oxide-mediated mechanisms account for coronary vasodilation during exercise. Circ Res. 1998;82:346–359
  31. Jackson WF. Potassium channels and regulation of the microcirculation. Microcirculation. 1998;5:85–90
  32. Jollis JG, Simpson RJ, Cascio WE, et al. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Am Heart J. 1999;138:S376–S380
  33. Katsuda Y, Egashira K, Ueno H, et al. Glibenclamide, a selective inhibitor of ATP-sensitive K+ channels, attenuates metabolic coronary vasodilatation induced by pacing tachycardia in dogs. Circulation. 1995;92:511–517
  34. Keung EC, Li Q. Lactate activates ATP-sensitive potassium channels in guinea pig ventricular myocytes. J Clin Invest. 1991;88:1772–1777
  35. Klamann A, Sarfert P, Launhardt V, et al. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J. 2000;21:220–229
  36. Lawrence CL, Proks P, Rodrigo GC, et al. Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia. 2001;44:1019–1025
  37. Lederer WJ, Nichols CG. Nucleotide modulation of the activity of rat heart ATP-sensitive K+ channels in isolated membrane patches. J Physiol. 1989;419:193–211
  38. Liu GX, Hanley PJ, Ray J, et al. Long-chain acyl-coenzyme A esters and fatty acids directly link metabolism to K(ATP) channels in the heart. Circ Res. 2001;88:918–924
  39. Marcus ML, Chilian WM, Kanatsuka H, et al. Understanding the coronary circulation through studies at the microvascular level. Circulation. 1990;82:1–7
  40. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19(Suppl):789–830
  41. Melchert PJ, Duncker DJ, Traverse JH, Bache RJ. Role of K(+)(ATP) channels and adenosine in regulation of coronary blood flow in the hypertrophied left ventricle. Am J Physiol. 1999;277:H617–H625
  42. Merkus D, Houweling B, Van Vliet M, Duncker DJ. Contribution of KATP+ channels to coronary vasomotor tone regulation is enhanced in exercising swine with a recent myocardial infarction. Am J Physiol. 2005;288:H1306–H1313
  43. Minamino T, Kitakaze M, Node K, et al. Inhibition of nitric oxide synthesis increases adenosine production via an extracellular pathway through activation of protein kinase C. Circulation. 1997;96:1586–1592
  44. Mukamal KJ, Nesto RW, Cohen MC, et al. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care. 2001;24:1422–1427
  45. Muller JM, Davis MJ, Chilian WM. Integrated regulation of pressure and flow in the coronary microcirculation. Cardiovasc Res. 1996;32:668–678
  46. Narishige T, Egashira K, Akatsuka Y, et al. Glibenclamide prevents coronary vasodilation induced by beta 1–adrenoceptor stimulation in dogs. Am J Physiol. 1994;266:H84–H92
  47. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol. 1995;268:C799–C822
  48. O'Keefe JH, Blackstone EH, Sergeant P, McCallister BD. The optimal mode of coronary revascularization for diabetics. A risk-adjusted long-term study comparing coronary angioplasty and coronary bypass surgery. Eur Heart J. 1998;19:1696–1703
  49. Pogatsa G, Koltai MZ, Jermendy G, et al. The effect of sulphonylurea therapy on the outcome of coronary heart diseases in diabetic patients. Acta Med Hung. 1992;49:39–51
  50. Reffelmann T, Klues HG, Hanrath P, Schwarz ER. Post-stenotic coronary blood flow at rest is not altered by therapeutic doses of the oral antidiabetic drug glibenclamide in patients with coronary artery disease. Heart. 2002;87:54–60
  51. Richmond KN, Tune JD, Gorman MW, Feigl EO. Role of K+ ATP channels in local metabolic coronary vasodilation. Am J Physiol. 1999;277:H2115–H2123
  52. Richmond KN, Tune JD, Gorman MW, Feigl EO. Role of K(ATP)(+) channels and adenosine in the control of coronary blood flow during exercise. J Appl Physiol. 2000;89:529–536
  53. Rytter L, Troelsen S, Beck-Nielsen H. Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care. 1985;8:230–234
  54. Samaha FF, Heineman FW, Ince C, et al. ATP-sensitive potassium channel is essential to maintain basal coronary vascular tone in vivo. Am J Physiol. 1992;262:C1220–C1227
  55. Sato T, Sasaki N, Seharasyeon J, et al. Selective pharmacological agents implicate mitochondrial but not sarcolemmal K(ATP) channels in ischemic cardioprotection. Circulation. 2000;101:2418–2423
  56. Song DK, Ashcroft FM. Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels. Br J Pharmacol. 2001;133:193–199
  57. Sturgess NC, Ashford MLJ, Cook DL, Hales CN. The sulphonylurea receptor may be an ATP-sensitive potassium channel. Lancet. 1985;2:474–475
  58. Tune JD, Richmond KN, Gorman MW, Feigl EO. K(ATP)(+) channels, nitric oxide, and adenosine are not required for local metabolic coronary vasodilation. Am J Physiol. 2001;280:H868–H875
  59. Vivaudou M, Forestier C. Modification by protons of frog skeletal muscle KATP channels: effects on ion conduction and nucleotide inhibition. J Physiol. 1995;486:629–645
  60. Weih M, Amberger N, Wegener S, et al. Sulfonylurea drugs do not influence initial stroke severity and in-hospital outcome in stroke patients with diabetes. Stroke. 2001;32:2029–2203
  61. Yamada M, Isomoto S, Matsumoto S, et al. Sulphonylurea receptor 2B and Kir6.1 form a sulfonylurea-sensitive but ATP-insensitive K+ channel. J Physiol. 1997;499:715–720

PII: S1050-1738(07)00004-7

doi: 10.1016/j.tcm.2006.12.003

Trends in Cardiovascular Medicine
Volume 17, Issue 2 , Pages 63-68 , February 2007

Article Tools

* Image Usage & Resolution